I don’t disagree with you on any of that. What probably bothers me the most is exactly what you said that they have so many subsidiaries.

All of these subsidiaries and basically no real profit and what they have that’s promising - Excellagen, it sounds like it’s on hold until they get funding.

They went on a ‘spending spree’ in getting all of these subsidiaries and a couple are at best questionable with what it cost them and the problems with who they dealt with to having some good subsidiaries and no real results.

I’m hoping things turn around, but everything rests on funding right now, which is worrisome.